Antibiotics in Necrotizing Soft Tissue Infections - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Antibiotics Year : 2021

Antibiotics in Necrotizing Soft Tissue Infections

Tomas Urbina
Keyvan Razazi
  • Function : Author
Clément Ourghanlian
  • Function : Author
Paul-Louis Woerther
Olivier Chosidow
Raphaël Lepeule
  • Function : Author
Nicolas de Prost


Necrotizing soft tissue infections (NSTIs) are rare life-threatening bacterial infections characterized by an extensive necrosis of skin and subcutaneous tissues. Initial urgent management of NSTIs relies on broad-spectrum antibiotic therapy, rapid surgical debridement of all infected tissues and, when present, treatment of associated organ failures in the intensive care unit. Antibiotic therapy for NSTI patients faces several challenges and should (1) carry broad-spectrum activity against gram-positive and gram-negative pathogens because of frequent polymicrobial infections, considering extended coverage for multidrug resistance in selected cases. In practice, a broad-spectrum beta-lactam antibiotic (e.g., piperacillin-tazobactam) is the mainstay of empirical therapy; (2) decrease toxin production, typically using a clindamycin combination, mainly in proven or suspected group A streptococcus infections; and (3) achieve the best possible tissue diffusion with regards to impaired regional perfusion, tissue necrosis, and pharmacokinetic and pharmacodynamic alterations. The best duration of antibiotic treatment has not been well established and is generally comprised between 7 and 15 days. This article reviews the currently available knowledge regarding antibiotic use in NSTIs.

Dates and versions

hal-04298182 , version 1 (21-11-2023)



Tomas Urbina, Keyvan Razazi, Clément Ourghanlian, Paul-Louis Woerther, Olivier Chosidow, et al.. Antibiotics in Necrotizing Soft Tissue Infections. Antibiotics, 2021, 10 (9), pp.1104. ⟨10.3390/antibiotics10091104⟩. ⟨hal-04298182⟩
2 View
0 Download



Gmail Facebook X LinkedIn More